Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona. 

UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health industries globally.

The LLiçà de Vall site occupies a surface area of 21,176 m2, a workforce of 89 people, and a production capacity of 160 m3 of reaction volume. It currently produces advanced intermediates and active pharmaceutical ingredients, which are exported to Europe, the United States, Latin America and Asia.

The facility meets Good Manufacturing Practices (GMPs) and holds the corresponding AEMPS (Spanish Health Agency) certification, as well as ISO14001:2005 certification covering environmental aspects. It is also audited by several international regulatory authorities such as the Korean FDA and the Japanese PMDA.

Esteve is a Spanish international pharmaceutical company headquartered in Barcelona. The company operates as a collection of organizations that span various areas related to healthcare. This includes Esteve Química; Esteve Pharmaceuticals; ISDIN (skin care), an alliance between ESTEVE and the PUIG Group; and Esteve Teijin Healthcare (ETH) in the field of home respiratory therapy with the Japanese group Teijin Pharma.

CCD Partners’ Matt Dixon, Peter Dixon, and Matthew Wise advised UQUIFA on this carve-out and divestment project. The project began with an initial scoping and strategic review phase, before launching a formal divestment process with a number of interested parties, and driving the project through due diligence to completion.

Staffan Schüberg, CEO of ESTEVE, commented:

''This operation is an excellent opportunity to increase our industrial capacity and serve our customers and patients worldwide, to improve people's health and be true to our purpose. We are advancing towards our vision of becoming an international proprietary specialty pharma and with this opportunity we will be able to expand our services to the global specialty pharma market''.

Matt Dixon, Managing Partner at CCD Partners, commented:

“We were engaged to find a new home for one of UQUIFA’s Spanish sites. I’m pleased to say we introduced several parties with strong interest and strategic rationale in acquiring the site and conducted a private auction process before settling on the best new owner, Esteve Quimica.”

 Saurabh Gurnurkar, Managing Director of UQUIFA Sciences, commented:

"The UQUIFA team is pleased that the LLiçà de Vall site will get a committed owner with the capacity to develop it to its full potential. This divestment will help UQUIFA streamline our Spanish operations in line with our strategic goals and better align with our customers' evolving needs.

My thanks to everyone on the CCD Partners team for getting this deal to the finish line. It was a pleasure working with each of you every step of the way, from the initial scoping exercise all the way through to final execution.”